Cargando…

Current status and advances of immunotherapy in nasopharyngeal carcinoma

The general immune landscape of nasopharyngeal carcinoma (NPC) renders immunotherapy suitable for patients with NPC. Immune checkpoint inhibitors (ICIs) based on programmed death-1/programmed death ligand-1 (PD-1/PD-L1) blockade have made a breakthrough with the approval of PD-1 inhibitor for refrac...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jian-Ying, Wei, Xiao-Li, Wang, Yi-Qin, Wang, Feng-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9083041/
https://www.ncbi.nlm.nih.gov/pubmed/35547095
http://dx.doi.org/10.1177/17588359221096214
_version_ 1784703334520717312
author Xu, Jian-Ying
Wei, Xiao-Li
Wang, Yi-Qin
Wang, Feng-Hua
author_facet Xu, Jian-Ying
Wei, Xiao-Li
Wang, Yi-Qin
Wang, Feng-Hua
author_sort Xu, Jian-Ying
collection PubMed
description The general immune landscape of nasopharyngeal carcinoma (NPC) renders immunotherapy suitable for patients with NPC. Immune checkpoint inhibitors (ICIs) based on programmed death-1/programmed death ligand-1 (PD-1/PD-L1) blockade have made a breakthrough with the approval of PD-1 inhibitor for refractory recurrence and/or metastatic (R/M NPC) and the approval of PD-1 inhibitor in combination with gemcitabine and cisplatin as first line for R/M NPC in 2021 in China. The incorporation of ICIs into the treatment paradigms of NPC has become a clinical hot spot and many prospective clinical studies are ongoing. In this review, we provide a comprehensive overview of the rationale for immunotherapy in NPC and current status, advances and challenges of immunotherapy in NPC based on published clinical data, and ongoing trials. We focus on the clinical application and advances of PD-1 inhibitor monotherapy and its combination with chemotherapy and summarize the clinical explorations of other immunotherapy approaches, for example, combination of PD-1/PD-L1 inhibitors with antiangiogenic inhibitor with molecular targeted agents, cancer vaccines, adaptive immunotherapy, and new ICI agents beyond PD-1/PD-L1 inhibitors in R/M NPC. We also describe the clinical studies’ status and challenges of ICIs-based immunomodulatory strategies in local advanced NPC and pay attention to the biomarker application for personalized immunotherapy of NPC in the hope to provide insights for clinical practice and future clinical studies.
format Online
Article
Text
id pubmed-9083041
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-90830412022-05-10 Current status and advances of immunotherapy in nasopharyngeal carcinoma Xu, Jian-Ying Wei, Xiao-Li Wang, Yi-Qin Wang, Feng-Hua Ther Adv Med Oncol Review The general immune landscape of nasopharyngeal carcinoma (NPC) renders immunotherapy suitable for patients with NPC. Immune checkpoint inhibitors (ICIs) based on programmed death-1/programmed death ligand-1 (PD-1/PD-L1) blockade have made a breakthrough with the approval of PD-1 inhibitor for refractory recurrence and/or metastatic (R/M NPC) and the approval of PD-1 inhibitor in combination with gemcitabine and cisplatin as first line for R/M NPC in 2021 in China. The incorporation of ICIs into the treatment paradigms of NPC has become a clinical hot spot and many prospective clinical studies are ongoing. In this review, we provide a comprehensive overview of the rationale for immunotherapy in NPC and current status, advances and challenges of immunotherapy in NPC based on published clinical data, and ongoing trials. We focus on the clinical application and advances of PD-1 inhibitor monotherapy and its combination with chemotherapy and summarize the clinical explorations of other immunotherapy approaches, for example, combination of PD-1/PD-L1 inhibitors with antiangiogenic inhibitor with molecular targeted agents, cancer vaccines, adaptive immunotherapy, and new ICI agents beyond PD-1/PD-L1 inhibitors in R/M NPC. We also describe the clinical studies’ status and challenges of ICIs-based immunomodulatory strategies in local advanced NPC and pay attention to the biomarker application for personalized immunotherapy of NPC in the hope to provide insights for clinical practice and future clinical studies. SAGE Publications 2022-05-07 /pmc/articles/PMC9083041/ /pubmed/35547095 http://dx.doi.org/10.1177/17588359221096214 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Xu, Jian-Ying
Wei, Xiao-Li
Wang, Yi-Qin
Wang, Feng-Hua
Current status and advances of immunotherapy in nasopharyngeal carcinoma
title Current status and advances of immunotherapy in nasopharyngeal carcinoma
title_full Current status and advances of immunotherapy in nasopharyngeal carcinoma
title_fullStr Current status and advances of immunotherapy in nasopharyngeal carcinoma
title_full_unstemmed Current status and advances of immunotherapy in nasopharyngeal carcinoma
title_short Current status and advances of immunotherapy in nasopharyngeal carcinoma
title_sort current status and advances of immunotherapy in nasopharyngeal carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9083041/
https://www.ncbi.nlm.nih.gov/pubmed/35547095
http://dx.doi.org/10.1177/17588359221096214
work_keys_str_mv AT xujianying currentstatusandadvancesofimmunotherapyinnasopharyngealcarcinoma
AT weixiaoli currentstatusandadvancesofimmunotherapyinnasopharyngealcarcinoma
AT wangyiqin currentstatusandadvancesofimmunotherapyinnasopharyngealcarcinoma
AT wangfenghua currentstatusandadvancesofimmunotherapyinnasopharyngealcarcinoma